Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 20, 2017

New Australian trial shows HPV screening efficacy for cervical abnormalities

A new clinical trial (Compass) conducted by Cancer Council NSW and the Victorian Cytology Service in Australia has demonstrated the efficacy of HPV screening for the detection of high-grade cervical abnormalities.

A new clinical trial (Compass) conducted by Cancer Council NSW and the Victorian Cytology Service in Australia has demonstrated the efficacy of HPV screening for the detection of high-grade cervical abnormalities.

The trial compared HPV screening to Pap tests (cytology) in subjects with substantial use of the HPV vaccine.

The screening was previously found to lower incidence and mortality due to cervical cancer by a minimum of 20%, indicating its accuracy, efficacy and safety.

Cancer Council NSW Research director professor Karen Canfell said: “We found that the HPV test was substantially more effective at picking up high-grade abnormalities compared to the Pap test.

“This adds to existing evidence about how much more accurate and effective HPV screening is. We now have a superior method for detecting not just the virus that causes cervical cancer, but also high-grade abnormalities.”

The trial is expected to confirm the efficacy of the new screening programme before a renewed National Cervical Screening Programme is implemented in the country in December.

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment
"The screening was previously found to lower incidence and mortality due to cervical cancer by a minimum of 20%, indicating its accuracy, efficacy and safety."

During the first phase of the trial, cervical samples were collected from approximately 5,000 women aged 25-64 years who visited for a routine screening at 47 participating sites in Victoria.

The samples were sent on the management pathway that is part of the upcoming renewed programme.

Victorian Cytology Service executive director associate professor Marion Saville said: “The results represent the first real-life demonstration of how the treatment pathways for primary HPV screening in HPV-vaccinated cohorts of women can work in practice.”

The ongoing second phase of the trial aims to include 121,000 subjects attending a routine screening or follow-up management.

The enhanced detection of high-grade abnormalities of precancerous lesions (CIN2 or higher) is expected to allow early treatment that results in long-term protection from development of CIN3 and invasive cancer.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU